National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pasireotide LAR (Signifor® LAR). HTA ID: 22034

Pasireotide LAR is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.


NCPE Assessment Process Complete
Rapid review commissioned 13/05/2022
Rapid review completed 16/06/2022
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that pasireotide LAR be considered for reimbursement*.


 *This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.